Oncopeptides Q3 loss after tax narrows 28% to SEK 43.97 million

Bitget2026/11/05 07:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oncopeptides’ third-quarter 2026 loss after tax narrowed 28% year over year to SEK 43.97 million.
Net sales rose 41% year over year to SEK 28.45 million in the quarter.
For January-September 2026, net sales climbed 62% year over year to SEK 84.93 million.
CHMP recommended expanding Pepaxti’s label to third-line multiple myeloma treatment.
Following the quarter, a directed share issue raised approximately SEK 100 million to advance the glioblastoma clinical program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncopeptides AB published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oncopeptides Q3 loss after tax narrows 28% to SEK 43.97 million

You may also like

Crypto prices